IF1 limits the ATP synthetic activity of the enzyme in cancer cells [47–49], as well as in normal mouse tissues in vivo [32, 50, 51], to favor the reprogramming of metabolism to an enhanced glycolytic phenotype. Here, ATP5IF1 is linked to cancer.